MSLN and hematologic disorder: MSLN has been extensively explored as an immunotherapeutic target in clinical trials for a variety of solid tumors, yet its therapeutic potential in hematological tumors has not yet been fully elucidated, necessitating more in-depth studies to characterize the expression pattern of MSLN in hematologic malignancies.